RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Clearside Biomedical Stock

Clearside Biomedical Stocks 2024

Clearside Biomedical Stocks

61.81 M

Ticker

CLSD

ISIN

US1850631045

WKN

A2ALP6

In 2024, Clearside Biomedical had 61.81 M outstanding stocks, a 0% change from the 61.81 M stocks in the previous year.

The Clearside Biomedical Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e61.81
2028e61.81
2027e61.81
2026e61.81
2025e61.81
2024e61.81
202361.81
202260.2
202159.91
202046.51
201938.17
201830.73
201725.31
201625.29
201519.59
201419.59
201319.59

Clearside Biomedical shares outstanding

The number of shares was Clearside Biomedical in 2023 — This indicates how many shares 61.807 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Clearside Biomedical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Clearside Biomedical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Clearside Biomedical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Clearside Biomedical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Clearside Biomedical Aktienanalyse

What does Clearside Biomedical do?

Clearside Biomedical Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of eye diseases and other medical conditions. The company was founded in 2011 by an experienced team of researchers and developers and is based in Alpharetta, Georgia. Clearside Biomedical Inc's history can be traced back to the groundbreaking research of Professor Henry Edelhauser, a renowned ophthalmologist and leading expert in the field of ophthalmology. Professor Edelhauser had the idea that by injecting drugs directly into the eye, specifically into the back part of the eye, more effective treatment could be achieved. Together with his team, he developed an innovative method for injecting drugs into the vitreous humor of the eye, which Clearside Biomedical Inc uses in its work. The business model of Clearside Biomedical Inc is based on the development and commercialization of therapies that rely on the intravitreal injection of drugs into the eye. The goal is to deliver drugs more effectively and precisely to the site of action, thus increasing the effectiveness of the treatment. The company focuses on the treatment of diseases of the posterior segment of the eye, such as age-related macular degeneration, diabetic retinopathy, or retinal vein occlusions. The various divisions of Clearside Biomedical Inc include research and development, clinical trials, manufacturing and marketing of therapies, as well as marketing and sales. The company places great importance on collaboration with leading scientists and regulatory bodies to ensure the effectiveness and safety of their products. Clearside Biomedical Inc's products include various innovative therapies for intravitreal injection, such as the drug Zuprata. Zuprata is a steroid specifically developed for the treatment of diseases of the posterior segment of the eye and has high efficacy. The drug is injected directly into the vitreous humor of the eye and has the advantage of being longer-lasting than other steroids. Another product of Clearside Biomedical Inc is the CLS-TA implant. The implant is based on an innovative technology that allows for continuous delivery of drugs over a longer period of time. The implant is directly implanted into the posterior part of the eye and can help increase the efficacy of drugs and reduce the number of necessary injections. Clearside Biomedical Inc has made significant progress in recent years and has successfully conducted several clinical trials. In 2019, the company received approval from the US Food and Drug Administration (FDA) for the marketing of Zuprata for the treatment of macular edema associated with uveitis. Overall, Clearside Biomedical Inc has a promising future. The company relies on innovative technologies and close collaboration with leading experts in the field of ophthalmology to develop new therapies and provide patients with better treatment options. Clearside Biomedical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Clearside Biomedical's Shares Outstanding

Clearside Biomedical's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Clearside Biomedical’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Clearside Biomedical’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Clearside Biomedical’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Clearside Biomedical stock

How many stocks are there of Clearside Biomedical?

The current number of stocks of Clearside Biomedical is 61.81 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Clearside Biomedical are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Clearside Biomedical evolved in recent years?

The number of shares of Clearside Biomedical has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Clearside Biomedical as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Clearside Biomedical?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Clearside Biomedical pay?

Over the past 12 months, Clearside Biomedical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Clearside Biomedical is expected to pay a dividend of 0 USD.

What is the dividend yield of Clearside Biomedical?

The current dividend yield of Clearside Biomedical is .

When does Clearside Biomedical pay dividends?

Clearside Biomedical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Clearside Biomedical?

Clearside Biomedical paid dividends every year for the past 0 years.

What is the dividend of Clearside Biomedical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Clearside Biomedical located?

Clearside Biomedical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clearside Biomedical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clearside Biomedical from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Clearside Biomedical pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Clearside Biomedical in the year 2023?

In the year 2023, Clearside Biomedical distributed 0 USD as dividends.

In which currency does Clearside Biomedical pay out the dividend?

The dividends of Clearside Biomedical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Clearside Biomedical

Our stock analysis for Clearside Biomedical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clearside Biomedical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.